Member Info for Toukankahmoon

Doct
It’s what you just posted that worries me about ramping on here.
If you really are all in, then that’s a very dangerous place to be. Never invest more than you can afford to lose. Avacta makes up about 30% of my current portfolio and that is far too much. But like a lot of others on here I do feel that the risk is worth what in a couple of years could be a good return.
Good luck

FFS I’m not saying it doesn’t work. That is unequivocal.

But I do believe that it isn’t mirroring mouse performance for some reason. But they will get a revolutionary life saving product to market it’s just going to take longer. And I expect to double or triple my investment this year.
Science Day needs to show IIs the road ahead to a profit producing product so they can be convinced it is worth putting money in now. And that is even more important given the unexpected further DE.

Tim
I don’t care about you but I am concerned that some naive investor will see all the positive posts and max out their credit cards to invest expecting a ten fold payback in a couple of months. It isn’t going to happen.

13thMonk
The figures you quote are for mouse metabolism. I still think that AVA6000 is excreted from human bodies a lot quicker. Hence the need to go to the next DE. BUT I DON’T SEE THIS AS A BAD THING.

Regarding “unequivocal “ that just says it’s clear and can’t be argued with. It isn’t a measure of how well it’s working. So stop posting it all the time. We don’t know how well it works and neither will we after Science Day. It’s still a good investment. I expect to double or treble my money this year but the SP isn’t going to go to £20. If you think it is you are delusional.

RAH
For the umpteenth time, they did not turn down £13M from PIs. The specific terms for that offer didn’t allow them to exceed the authorised amount.
You know that this is the sort of fact twisting that really winds me up. Perhaps that’s why you do it. It must be because most of your non-abusive posts are well researched and informative.

Nothing to argue with here. Even the rampers have finally come to their senses and recognised the reality of where we are re Science Day et Al.

Thom
What they need to do is get all the big investors to a Science Day to convince them it’s worth investing and then put a shed load of shares out at 10% discount off SP. All the capital they need.

£55M was specifically for Diagnostics Division (does that still exist?) and Launch acquisition.

You rampers are a bunch of kids. Whether you believe it or not Wyn said “sellers” not “sales”. Not that it matters. Just one of many examples of picking words out of a post that doesn’t fit your narrative and quoting it out of context so you can pick an argument.
Oh well enjoy the squabble.
Same time tomorrow?

Presume you’ve all read the panel session transcripts by now. Good positive endorsement of the the move to Scale Space by our Fiona but no hints on AVA6000.

Nice bounce today BTW.

Buen
If you want the bashers/realists back, just keep posting that it’s going to be £20 by the end of the month.

Well if I were one of you potty mouthed rampers it might cause issues, but I’m fairly polite.

Tim
You being silly? Surely not?

Buen
Think you’re getting close to breaking the BB rules.
But what do you want to know?

No

Despite the data rich clinical trial I don’t think any more details will be given. After all the IIs just want to know whether it’s gonna be worth their while to subscribe in the offer that will be announced right afterwards. So they will want to know timescales to market and when the next products will be coming along plus any licensing deals in the bag.

JT

Good explanation including point that AVA6000 keeps circulating past the TME and hence cleaving more Dox leading to 18x (or whatever) in tumour versus blood/heart.
But, as I keep asking, what if the metabolism of humans is such that the AVA6000 is excreted from the body much faster in humans? Then the TME would not be getting the same exposure to AVA6000 (and therefore Dox). Therefore we might have to go to higher dose levels to get the desired efficacy. And hence prolonging P1a.

As I said before, I don’t necessarily see this as a bad thing. And it would explain what is happening at the moment.

Abuse incoming I guess.

And if that’s the case I don’t see it as a bad thing because it will make it a safer treatment. But it would then require higher or more frequent doses. That could explain the need for a further DE.

Benharper
Thank you for polite answer.
But it’s the behaviour of the uncleaved AVA6000 in the blood that I am wondering about. Is it being excreted from the human body at a far faster rate than from the mouse body and therefore the TME has less exposure?

Simple question. Why all the abuse?

It works with little or no side effects. But the question remains why would Avacta be coy about the amount of Dox in the TME. It still makes no sense to me unless AVA6000 is being excreted from human body far quicker than mouse body.